The Prostate · 2011 · 25 citations · 24 references
MedicineOncologyUrologyCancer EpidemiologyEpidemiologyProstate DiseaseBiomarkers In Genitourinary CancerCancer DisparitiesPatient StratificationProstate CancerProstate-specific Antigen TestingRisk StratificationProstate Cancer Risk StratificationProstate-specific Antigen Cutoff ValuesProstate-specific Antigen VelocityRisk Stratification Using Prostate-specific Antigen
BACKGROUND: Baseline prostate specific antigen (PSA) and PSA velocity used to stratify subsequent prostate cancer risk in young men may not directly applicable to all populations. We sought to compare the baseline PSA and PSA velocity among ethnic groups. PATIENTS AND METHODS: Chinese, African-American (AA), and Caucasian-American (CA) men aged ≤50 years old without prostate cancer were used to identify baseline PSA and PSA velocity. The differences of baseline PSA and PSA velocity between races were assessed. The important cutoffs of baseline PSA and PSA velocity were used to stratify patients among races. RESULTS: Four thousand two hundred six Chinese, 997 AA, and 2,030 CA were included. The rates of baseline PSA of ≥1.0, ≥2.5, and ≥4.0 ng/ml was 24.4%, 4.2%, and 2.1% in Chinese, 30.7%, 5.2%, and 1.8% in AA, 29.7%, 5.3%, and 2.8% in CA, respectively. The rates of PSA velocity of ≥0.35, ≥0.75, and ≥1.0 ng/ml/year was 6.0%, 3.1%, and 2.6% in Chinese, 5.3%, 2.3%, and 1.7% in AA, 5.4%, 3.5%, and 3.3% in CA, respectively. Chinese had a lower baseline PSA and higher PSA velocity as compared to AA and CA. Baseline PSA and PSA velocity in AA had no statistical differences as compared to CA. CONCLUSIONS: The distributions of baseline PSA and PSA velocity in young men among Chinese, AA, and CA races are different. These characteristics shall be taken into account when using these variables to stratify risk of prostate cancer in young men.
24
Ahmedin Jemal, Rebecca L. Siegel, Jiaquan Xu et al. · CA A Cancer Journal for Clinicians · 2010 · 12.6K citations · Full text
Mortality Results from a Randomized Prostate-Cancer Screening Trial
Gerald L. Andriole, E. David Crawford, Robert L. Grubb et al. · New England Journal of Medicine · 2009 · 2.9K citations · Full text
Prostate Specific Antigen Best Practice Statement: 2009 Update
Kirsten L. Greene, Peter C. Albertsen, Richard J. Babaian et al. · The Journal of Urology · 2009 · 520 citations